Remote Ischaemic Preconditioning to Prevent Dialysis Induced Cardiac Injury

Randomized Controlled Trial of Remote Ischaemic Preconditioning to Protect Against Dialysis Induced Cardiac Injury in Haemodialysis: Low Vs. High Intensity

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02630355

Enrollment

Registered

2015-12-15

Start date

2016-01-31

Completion date

2018-12-31

Last updated

2020-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Hemodialysis

Brief summary

This study evaluates the use of remote ischaemic preconditioning for the prevention of dialysis induced cardiac injury. The study uses four arms to test different frequencies of application to ascertain which, if any, is most successful at reducing dialysis induced cardiac injury.

Interventions

OTHERRemote Ischaemic Preconditioning

Inflation of blood pressure cuff in lower limb

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients having haemodialysis treatment at least 3 times per week at a London Health Sciences Centre facility 2. Male and female, age≥16 years old.

Exclusion criteria

1. Not meeting inclusion criteria 2. Exposure to haemodialysis for \<90 days prior to recruitment 3. Severe heart failure (New York Heart Association grade IV) 4. Cardiac transplant recipients 5. Mental incapacity to consent 6. Declined to participate 7. Taking cyclosporin 8. Taking ATP-sensitive potassium channel opening or blocking drugs

Design outcomes

Primary

Measure	Time frame
The primary outcome will be a reduction in the number of left ventricular segments undergoing a greater than 30% reduction in longitudinal strain as detected by echocardiography at final study visit	4 weeks

Secondary

Measure	Time frame
Number of segments undergoing >30% reduction in longitudinal strain at intervention, week 1, week 2 and week 3 visits	up to 3 weeks
Difference between pre and peak global longitudinal strain at intervention, week 1, week 2 and week 3 visits	up to 3 weeks
Change in pre-dialysis global longitudinal strain between baseline and final study visit	between 1 and 4 weeks
Change in Troponin-T, Plasma IL-6 and N-Type proBNP at intervention, first follow-up and final visit	up to 4 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026